A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

NCT07391761 | Not Yet Recruiting FDA Drug

• 1 other identifier: C1071049
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 4

Brief Summary

The purpose of this study is to evaluate:

• What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan?
• What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan?
• What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Conditions

Refractory Multiple Myeloma (RRMM)

Outcome Measures

Primary Outcomes (6)

• rwTTR (real-world time to response)

  Time from index date to the first documented real-world response.

  At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

• rwORR (real-world overall response rate)

  Proportion of patients achieving real-world overall response at predefined assessment time points.

  At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

• rwDOR (real-world duration of response）

  Time from the first documented real-world response to real-world disease progression, death, or end of study.

  From first response until 18 months

• rwPFS (real-world progression-free survival)

  Time from index date to the first documented real-world disease progression or death.

  From initiation of elranatamab treatment (index date) until 18 months

• rwOS (real world overall survival)

  Time from index date to death from any cause.

  From initiation of elranatamab treatment (index date) until 18 months

• rwTTNT (real world time to next treatment)

  Time from index date to initiation of the next line of anti-myeloma therapy or end of study.

  From initiation of elranatamab treatment (index date) until 18 months

Secondary Outcomes (10)

• Demographic: Age

  At baseline

• Demographic: Sex

  From MM diagnosis until index date, and from index date until 18 months

• Anthropometric Measures

  At baseline

• ECOG Performance Status

  At baseline

• Myeloma-related Clinical Characteristics

  At baseline

Study Arms (1)

Elranatamab in Patients with Relapsed and/or Refractory Multiple Myeloma

Patients with Relapsed and/or Refractory Multiple Myeloma treated with Elranatamab

Drug: Non intervention

Interventions

Non intervention DRUG

Non intervention

Elranatamab in Patients with Relapsed and/or Refractory Multiple Myeloma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study population will consist of RRMM patients who have initiated elranatamab in consistent with the local health authority approved product label

You may qualify if:

• Patients age ≥ 18 years at the initiation of elranatamab
• Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
• Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

You may not qualify if:

• Patients who participated in any prior clinical trials using elranatamab.

Sponsors & Collaborators

• Pfizer: lead

Study Sites (4)

Kaohsiung Chang Gung Memorial Hospital

Kachsiung, 833, Taiwan

Location

Taichung Veterans General Hospital

Taichung, 40705, Taiwan

Location

Taipei Veterans General Hospital

Taipei, 11217, Taiwan

Location

Linkou Chang Gung Memorial Hospital

Taoyuan, 333, Taiwan

Location

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Central Study Contacts

Pfizer CT.gov Call Center

CONTACT

1-800-718-1021; ClinicalTrials.gov_Inquiries@pfizer.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 15, 2025
• First Posted: February 6, 2026
• Study Start: April 30, 2026
• Primary Completion (Estimated): January 31, 2028
• Study Completion (Estimated): January 31, 2028
• Last Updated: May 6, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

TW (4)